Overview of Cardiovascular and Diabetes Medications
Drugs that are effective in reducing cardiovascular issues and diabetes are integral to modern medicine. A recent study, known as the ACE Trial, assessed the efficacy of acarbose in lowering the incidence of cardiovascular disease and diabetes.
Significance of the Study in China
With over 230 million individuals affected by heart disease in China, the need for effective medication in this population is critical. Due to factors such as population growth and increased life expectancy, the incidence of cardiovascular events in China is projected to rise by 50% between 2010 and 2030.
Understanding Acarbose
Acarbose is an alpha-glucosidase inhibitor that prevents carbohydrate digestion. Its potential to reduce the occurrence of cardiovascular episodes in patients with coronary heart disease has led to the establishment of the Acarbose Cardiovascular Evaluation trial (ACE Trial). This initiative aimed to evaluate whether acarbose could reduce cardiovascular events among Chinese patients with established coronary heart disease, impaired glucose tolerance, and type 2 diabetes.
Details of the ACE Trial
Trial Design
The ACE Trial was a randomized, double-blind, phase 4 study that involved Chinese patients aged 50 years and older, all of whom had coronary heart disease and impaired glucose tolerance. The recruitment took place across 176 hospital outpatient clinics in China.
Participant Criteria and Treatment
Participants with impaired glucose tolerance, a history of myocardial infarction, unstable angina, or stable angina were randomly assigned to receive either 50 mg of acarbose or a placebo. Prior to the trial, patients had to have taken at least 80% of the placebo medication, and they discontinued previous treatments as necessary. Investigators provided all participants with lifestyle recommendations regarding diet, exercise, and smoking cessation. Existing cardiovascular therapies, such as blood pressure medications, beta blockers, statins, antiplatelet agents, and inhibitors of the renin-angiotensin-aldosterone system, were adjusted according to international treatment guidelines.
Strengths of the Trial
The trial’s strengths included a substantial number of participants and an extended follow-up period for this high-risk population.
Findings on Acarbose and Cardiovascular Outcomes
Although initial expectations suggested that acarbose would reduce cardiovascular-related outcomes, the results showed otherwise. Acarbose did not significantly decrease the rates of cardiovascular death, non-fatal myocardial infarction, non-fatal stroke, hospital admissions for unstable angina, or heart failure. Nevertheless, it was effective in reducing the risk of developing incidental diabetes by 18%. Researchers propose that while there was no direct impact of acarbose on cardiovascular outcomes in the ACE trial, potential indirect effects should not be overlooked.
Conclusion
This study highlights the complexities of treating cardiovascular disease and diabetes and underscores the need for continued research in this vital area of healthcare.
Reference
Holman, R. R., Coleman, R. L., Chan, J. C. N., et al. (2017). Effects of acarbose on cardiovascular and diabetes outcomes in patients with coronary heart disease and impaired glucose tolerance (ACE): a randomized, double-blind, placebo-controlled trial. *Lancet Diabetes Endocrinol*.